Among the promising areas of retinal disease research are innovative approaches targeting pan-vascular endothelial growth factor inhibition. The treatment landscape for retinal diseases is advancing ...

Investigators published a recent case report 1 that described the development of bilateral retinal detachments in a teenager. The patient was an otherwise healthy 19-year-old man who had been referred ...

The closing of the merger is expected to occur as soon as practicable, subject to the satisfaction or waiver of the remaining customary closing conditions. Kalaris Therapeutics, Inc. and AlloVir, ...

The ReNEW study for dry AMD is evaluating the efficacy, safety, and pharmacokinetics of daily subcutaneous injections of elamipretide, wa first-in-class mitochondria-targeted investigational ...

Yu reviewed the benefits and limitations of various electrophysiologic technologies in a diverse group of inflammatory conditions affecting the retina and optic nerve. Ophthalmic electrophysiology is ...

Chinese investigators found that renal dysfunction is a risk factor associated with the efficacy of intravitreal conbercept (IVC) injections (Lumitin, Chengdu Kanghong Biotech Co., Ltd.) for treating ...

Yehia Hashad, MD, has been appointed to the board of directors and as a member of its science committee for Unity Biotechnology Inc. In the company’s press release 1, Anirvan Ghosh, PhD, chief ...

4D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) from the retina with a single, safe, intravitreal injection.

A total of 43 patients who recovered from the SARS-CoV-2 infection with mild pneumonia were included along with 45 healthy individuals. Researchers from Istanbul, Turkey, conducted a study that found ...

This database could enhance the workflow of eye care professionals with its in-depth reference data for retinal layer thickness and optic nerve head metrics.

The findings were from 6 patients in the first low-dose cohort of the ongoing first-in-human trial (NCT04627428).